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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of thromboprophylaxis in trauma patients on mortality and incidence of DVT and PE.
To compare the effects of different thromboprophylaxis interventions and their relative effects according to the type of trauma.
B A C K G R O U N D
Description of the condition
Trauma is one of the leading causes of death and disability in
young people (Evans 2003).Worldwide, about five million people
die as a result of trauma every year (WHO 2008). For patients
who reach hospital within one hour of trauma (called the ’golden
hour’), blood loss and traumatic brain injury are the main causes
of death (Sauia 1995). For patients who survive beyond the first
day, multiple organ failure, central nervous system (CNS) failure
and venous thromboembolism (VTE) are the principal causes of
death (Acosta 1998).
Trauma patients are at known risk of entering into a hyperco-
agulable state. Mechanisms of hypercoagulability in the trauma
setting include stasis, vessel wall dysfunction and alterations in
clotting mechanisms (Virchow’s triad). Injured patients are often
immobilized after high-energy trauma. Being in a static position
causes a reduction in venous blood returns and a decrease in the
supply of oxygen and nutrients to endothelial cells. In addition,
endothelial damage caused by direct trauma to the vessels causes
the exposition of tissue factor bearing cells. This initiates a proco-
agulant factor that amplifies the coagulant response. These tissue
factor bearing cells move to the cell surface of the platelets, which
produces a propagation of the signal through the accumulation of
thrombin, activated cofactors andmore platelets, inducing throm-
bosis (Hoffman 2001).
On the other hand, trauma patients experience a reduction of fibri-
nolytic pathways that seems to result from increased plasminogen
activator inhibitor (PAI) 1. PAI 1 inhibits tissue plasminogen acti-
vator (tPA) and thus decreases the production of plasmin (Rogers
1995; Kelsey 2000). Coagulation abnormalities and the reduced
ability to use the muscular pump of the calf in the injured pa-
tient can produce deep venous thrombosis (DVT) in the inferior
and superior extremities (Spaniolas 2008). When the thrombus
extends to the proximal segments, there is an increased risk of clot
migration to the lungs and a fatal outcome (Geerts 2008).
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Trauma patients are at high risk for DVT, with an incidence of
11.8% to 65% (Sevitt 1961; Geerts 1994; Velmahos 2000). The
incidence varies according to the method used to measure the
DVT and the location of the thrombosis. Incidence of thrombosis
in the thigh (proximal DVT) is estimated at 18% (Geerts 1994).
The incidence of pulmonary embolism (PE) is estimated be-
tween 1.5%and 20% (Shackford 1988;O’Malley 1990; Velmahos
2000). Many risk factors for DVT and PE in trauma patients
have been identified, such as spinal cord injury; lower extrem-
ity and pelvic fractures; need for surgical procedures; increasing
age; femoral venous line insertion or surgical repair of venous in-
juries; prolonged immobility; long duration of hospital stay; sever-
ity of the trauma andmechanism of injury (Geerts 1994; Knudson
1994; Frezza 1996; Velmahos 2000; Cipolle 2002; Rogers 2002;
Meissner 2003).
Description of the intervention
Thromboprophylaxis describes any intervention used to prevent
the development of VTE, and can be categorized into mechanical
and pharmacological interventions.
External mechanical devices such as graded compression devices
or intermittent pneumatic compression (IPC) have been shown
to be effective in preventing DVT, but they cannot be used in
patients with lower extremity trauma (Fisher 1995; Elliott 1999;
Velmahos 2000). Internal mechanical devices are used to prevent
the migration of thrombus from DVT to the lungs, thus prevent-
ing PE. One such device is the inferior vena cava filter (IVCF)
which may be particularly useful in trauma patients because of the
risk of ongoing bleeding at injured sites (McMurty 1999).
Pharmacological thromboprophylaxis was first described in the
1940s by Bauer 1944, and since then a number of interventions
have been proposed. The anticoagulant effect of unfractionated
heparin (UH) is initiated by the activation of antithrombin III
(ATIII). The ATIII/heparin complex inactivates the thrombin fac-
tor IIa, and factors Xa, IXa, XIa and XIIa. However, UH is asso-
ciated with a number of adverse events, such as thrombocytope-
nia. More recently, alternatives such as low molecular weight hep-
arin (LMWH), a derivative of UH, have been proposed. LMWH
acts in the same way as UH, but its low molecular weight frag-
ments reduce the binding to other cells and proteins (and it also
has a major affinity to factor Xa) (Hirsh 2004). These drugs have
potential as effective prophylactic interventions for trauma, al-
though there is concern due to the associated increased risk of
bleeding (Geerts 1996; Haentjens 1996; Knudson 1996; Cohn
1999). Other methods of thromboprophylaxis, such as anticoag-
ulants (warfarin) or antiplatelets (aspirin), seem less practical for
use in critically ill patients, because of their delayed action and
oral presentation. Pentassacharides (a new class of synthetic selec-
tive factor Xa inhibitor, with parenteral presentation which does
not bind to platelets, other cells or proteins) have been studied as
prophylaxis in surgical orthopedic patients and have been shown
to be as effective as UH and LMWH (Nijkeuter 2004).
How the intervention might work
Due to prolonged rest and coagulation abnormalities, trauma pa-
tients are at an increased risk of thrombus formation. Thrombo-
prohylaxis, either mechanical or pharmacological, may decrease
the mortality and morbidity in trauma patients who survive be-
yond the first day treated in hospital, decreasing the risk of DVT
and PE in this population. A previous Cochrane review focusing
on high-risk patients indicated that combined methods (pharma-
cologic and mechanical interventions) decreased the incidence of
DVT (Kakkos 2008). However, this systematic review did not ex-
amine the effects in the subgroup of trauma patients.
Why it is important to do this review
Trauma patients are at an increased risk of VTE, and thrombo-
prophylaxis has the potential to be effective in this population.
However, trauma patients are at an increased risk of bleeding, one
of the adverse events associated with pharmacological interven-
tions. For some trauma patients with injured extremities, the use
of mechanical interventions (e.g. external mechanical compres-
sion) is not feasible. A previous systematic review (Velmahos 2000)
did not find evidence of effectiveness for either pharmacological
or mechanical interventions. However, this systematic review was
conducted 10 years ago and most of the included studies were of
poor quality. Since then new trials have been conducted. Although
current guidelines (Rogers 2002; Geerts 2008) recommend the
use of thromboprophylaxis in trauma patients, there has not been
a comprehensive and updated systematic review since the one pub-
lished by Velmahos and collaborators. Furthermore, there are still
uncertainties about the relative benefit of interventions for differ-
ent subgroups of trauma patients. Therefore it is necessary to con-
duct a systematic review to establish whether the effect of different
thromboprophylaxis interventions varies according to the type of
trauma, location of the trauma, severity of trauma and type of
management (surgical or medical management).
O B J E C T I V E S
To assess the effects of thromboprophylaxis in trauma patients on
mortality and incidence of DVT and PE.
To compare the effects of different thromboprophylaxis interven-
tions and their relative effects according to the type of trauma.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
Randomized controlled clinical trials.
If we identify randomized cross-over trials, we will include data
from the first experimental period only.
Types of participants
Patients of any age with any type of trauma. We will exclude trials
that only recruited outpatients, trials that only recruited elderly
patients with hip fractures, or patients with acute spinal cord in-
juries.
Types of interventions
We will include trials reporting the use of any of the following
methods:
1. Unfractionated heparin (UH).
2. Low weight molecular heparin (LWMH).
3. Mechanical methods: graded compression stocking, and
sequential compression devices.
4. Oral anticoagulants (i.e. warfarin).
5. Antiplatelet drugs (i.e. aspirin).
6. Pentassacharides.
7. Pulmonary embolism prophylaxis (i.e. inferior vena cava
filter (IVCF)).
We will compare the effects of any intervention with placebo, and
any two interventions (e.g. LMWH versus UH) or combination
of interventions (UH plus mechanical methods versus UH).
Types of outcome measures
Primary outcomes
The primary outcomes will be mortality, incidence of DVT and
PE.
Secondary outcomes
The secondary outcomes will be the incidence of adverse events,
such as:
• bleeding (major and minor);
• whether the adverse event (bleeding of the injured site,
intracranial bleeding, gastrointestinal bleeding, epistaxis, etc.)
required transfusion or any procedure to control it;
• and other adverse events as defined by the study authors.
Search methods for identification of studies
Wewill not restrict searches by date, language or publication status.
Electronic searches
We will search the following electronic databases:
• Cochrane Injuries Group Specialised Register (to latest
version);
• Cocnrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library, latest issue);
• MEDLINE (Ovid SP) (1950 to most recent date available);
• EMBASE (Ovid SP) (1980 to most recent date available);
• ISI Web of Science: Science Citation Index Expanded (SCI-
EXPANDED) (1970 to most recent date available);
• ISI Web of Science: Conference Proceedings Citation
Index-Science (CPCI-S) (1990 to most recent date available);
• ZETOC (to most recent date available);
• LILACS (BIREME) (1982 to most recent date available);
• PubMed (www.ncbi.nlm.nih.gov/sites/entrez/) (to most
recent date available).
We will base searches on the MEDLINE search strategy listed in
Appendix 1, and adapt it to the specifications of each of the other
databases.
Searching other resources
We will search the reference lists for all relevant material and for
further potentially eligible studies. We will search the Internet
using the Google (www.google.com) search engine with selected
terms from the above strategy to identify any further unpublished
or grey literature. We will browse the following clinical trials web-
sites for complete and ongoing trials:
• www.clinicaltrials.gov;
• Controlled Trials metaRegister (www.controlled-trials.com).
Data collection and analysis
Selection of studies
Two authors (LB and PP) will independently examine titles, ab-
stracts, and keywords of citations from electronic databases for
eligibility. We will obtain the full text of all potentially relevant
records and two authors will independently assess whether each
meet the pre-defined inclusion criteria. We will resolve any dis-
agreement through discussion with a third author (CM). If there
is ambiguous or missing information, the authors will contact in-
vestigators of the study to clarify study eligibility.
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Data extraction and management
Two authors (LP and PP) will extract data independently, using
a standardized data extraction form. LB will enter the extracted
information into Review Manager for analysis (RevMan 2008).
We will extract data on the following characteristics.
1. General Information: title, authors, source of publication,
country, published or not, language and year of publication.
2. Trial characteristics: study design and information that
meets The Cochrane Collaboration’s tool for assessing risk of
bias.
3. Participants: sample size, inclusion criteria, exclusion
criteria, location of trauma (brain, chest, abdomin, pelvis,
extremity, polytrauma), severity of trauma (ISS, RTS, or
according to the scale used by the trialists), type of injury (blunt
or penetrating), and type of surgical procedure (non-operative or
surgical management).
4. Intervention: type and dose of thromboprophylaxis used,
type and dose of control or placebo used.
5. Outcomes: incidence of mortality, incidence of DVT
(symptomatic or asymptomatic) and diagnostic test used,
incidence of PE and diagnostic test used. Incidence of adverse
events as follows: any bleeding, major bleeding defined as use of
transfusion or any procedure to control bleeding (bleeding from
the injured site, gastrointestinal bleeding, brain bleeding,
epistaxis, etc.) and minor bleeding. And other outcomes
recorded by the trialists.
6. Results: number of patients in each group, missing patients.
7. Subgroup characteristics: number of patients by localization
of trauma, by severity, by type (blunt or penetrating), by type of
management (surgical or non-surgical).
8. Other information: funding source.
Assessment of risk of bias in included studies
Two authors (LB and PP) will assess the risk of bias of each in-
cluded study according to the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2008). We will assess the follow-
ing: sequence generation, allocation concealment, blinding, in-
complete outcome data, and selective outcome reporting. We will
complete risk of bias tables based on the above criteria. These will
incorporate the review authors’ judgement (’Yes’ for low risk of
bias; ’No’ for high risk of bias, or ’Unclear’) and description of the
design, conduct or observations that underlie the judgement, for
each domain in each included study. We will resolve any disagree-
ment by consulting a third author (CM).
Measures of treatment effect
Dichotomous data: We will calculate risk ratios (RR) and 95%
confidence intervals (CIs). We will also calculate number needed
to treat (NNT) and number needed to harm (NNH).
Continuous data:We will calculate themean difference (MD) and
95% CIs when the same scale is used in a similar manner across
studies. If results for continuous outcomes are reported using dif-
ferent scales or different versions of the same scale, we will calcu-
late the standardised mean difference (SMD) and 95% CIs.
Dealing with missing data
We will attempt to contact the study authors for missing informa-
tion.
Assessment of heterogeneity
We will examine trial characteristics in term of participants, inter-
ventions and outcomes for evidence of clinical heterogeneity. We
will examine statistical heterogeneity by both the I2 statistic and
Chi2 test. The I2 statistic describes the percentage of total variation
across studies due to heterogeneity rather than chance. A value of
0% indicates no observed heterogeneity, and larger values show
increasing heterogeneity; substantial heterogeneity is considered
to exist when I2 is larger than 50%. For the Chi2 test, we will use
a P value of less than 0.10 to indicate the presence of statistically
significant heterogeneity.
Assessment of reporting biases
We will assess reporting bias using funnel plots.
Data synthesis
If the included trials are clinically homogeneous and there is no evi-
dence of statistical heterogeneity thenwewill conduct ameta-anal-
ysis. For dichotomous outcomes, we will use the Mantel-Haen-
szel fixed effect method. For continuous outcomes we will use the
fixed-effect inverse-variance method.
Because different effects are expected according to the interven-
tion, we will perform data synthesis separately for each type (e.g.
UH, LWMH or mechanical devices).
If there is any evidence of clinical or statistical heterogeneity, we
will not conduct ameta-analysis, butwill instead present the results
in a narrative form.
Subgroup analysis and investigation of heterogeneity
If there are sufficient data we plan to perform the following sub-
group analyses:
• type of trauma (blunt, penetrating);
• location of the trauma (brain, chest, abdominal, pelvis,
extremity or polytrauma);
• severity of trauma defined with ISS or other similar scores;
• management (surgical or medical management);
• diagnostic method.
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Sensitivity analysis
We will perform a sensitivity analysis to investigate whether the
conclusions are robust. We will examine the effect of excluding
certain studies according to their risk of bias. We will report the
data synthesis for all the included studies and will repeat the cal-
culations after excluding studies judged as having a high risk of
bias for allocation concealment. We will also examine the effect of
reporting a different effect measure (odds ratio) for the dichoto-
mous outcomes.
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A P P E N D I C E S
Appendix 1. Search strategy
MEDLINE 1950 to April Week 3 2009
1.exp “Wounds and Injuries”/
2.(wound* or trauma* or injur* or fracture* or burn* or stab* or shot* or shoot* or lacerat* or accident*).mp. [mp=title, abstract,
subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
3.1 or 2
4.exp Venous Thromboembolism/
5.exp Venous Thrombosis/
6.exp Pulmonary embolism/
7.exp Thrombophlebitis/
8.(thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or thromboph*).ab,ti.
9.(deep* adj3 (vein* or ven*) adj5 (thromb* or embol*)).ab,ti.
10.((pulmonary or lung*) adj3 (thromb* or embol*)).ab,ti.
11.(DVT or PE or VTE).ab,ti.
12.4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13.(thromboprophylaxis or prophylactic* or prophylaxis).ab,ti.
14.exp Heparin/
15.exp Heparin, Low-Molecular-Weight/
16.exp Heparinoids/
17.exp Stockings, Compression/
18.exp Intermittent Pneumatic Compression Devices/
19.exp Stockings, Compression/
20.exp Anticoagulants/
21.exp Warfarin/
22.exp Platelet Aggregation Inhibitors/
23.exp Aspirin/
24.Heparin*.ab,ti.
25.((compression or impulse or pneumatic or elastic*) adj3 (device* or stocking* or hose* or dressing* or bandage*)).ab,ti.
26.(Anticoagulant* or Warfarin or Coumadin* or apo-warfarin or gen-warfarin or warfant or Coumadin or aldocumar or te-
dicumar).ab,ti.
27.(Antiplatelet* or (platelet* adj3 aggregation adj3 inhibit*) or ((blood or platelet*) adj3 (antagonist* or antiaggrega*))).ab,ti.
28.(Aspirin* or acetylsalicylic acid or acylpyrin or aloxiprimum or colfarit or dispril or easprin or ecotrin or endosprin or magnecyl or
micristin or polopirin or polopiryna or solprin or solupsan or zorprin or acetysal).ab,ti.
29.exp Vena Cava Filters/
30.((vena adj3 cava adj3 filter*) or (umbrella adj3 filter*)).ab,ti.
31.(Pentassacharide* or fondaparinux).ab,ti.
32.or/13-31
33.randomi?ed.ab,ti.
34.randomized controlled trial.pt.
35.controlled clinical trial.pt.
36.placebo.ab.
37.clinical trials as topic.sh.
38.randomly.ab.
39.trial.ti.
40.33 or 34 or 35 or 36 or 37 or 38 or 39
41.(animals not (humans and animals)).sh.
42.40 not 41
43.3 and 12 and 22 and 42
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H I S T O R Y
Protocol first published: Issue 1, 2010
D E C L A R A T I O N S O F I N T E R E S T
None known.
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